Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients

[1]  P. Ponikowski,et al.  Signature of circulating microRNAs in patients with acute heart failure , 2016, European journal of heart failure.

[2]  P. Geurts,et al.  Circulating microRNA-based screening tool for breast cancer , 2015, Oncotarget.

[3]  P. Cardelli,et al.  Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients , 2016, Tumor Biology.

[4]  A. Mebazaa,et al.  Circulating microRNAs and Outcome in Patients with Acute Heart Failure , 2015, PloS one.

[5]  E. Gonzalez-Billalabeitia,et al.  Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis , 2015, Breast Cancer Research and Treatment.

[6]  T. Uehara,et al.  Plasma miR‐208 as a useful biomarker for drug‐induced cardiotoxicity in rats , 2015, Journal of applied toxicology : JAT.

[7]  V. Bours,et al.  Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR‐34a and miR‐122 Expression , 2014, Journal of cellular physiology.

[8]  J. Fuscoe,et al.  Early biomarkers of doxorubicin-induced heart injury in a mouse model. , 2014, Toxicology and applied pharmacology.

[9]  T. Tuschl,et al.  Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers , 2014, Proceedings of the National Academy of Sciences.

[10]  Randolph P. Martin,et al.  Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. , 2014, Journal of the American College of Cardiology.

[11]  H. Maddock,et al.  Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. , 2014, Clinical science.

[12]  M. Rousseau,et al.  Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. , 2014, International journal of cardiology.

[13]  F. Jin,et al.  Serum soluble ST2 is associated with ER-positive breast cancer , 2014, BMC Cancer.

[14]  Y. Vorasettakarnkij,et al.  Serum NT‐proBNP in the early detection of doxorubicin‐induced cardiac dysfunction , 2013, Asia-Pacific journal of clinical oncology.

[15]  H. Hermeking,et al.  MicroRNA-34a regulates cardiac ageing and function , 2013, Nature.

[16]  L. Zentilin,et al.  Functional screening identifies miRNAs inducing cardiac regeneration , 2012, Nature.

[17]  R. Vasan,et al.  Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. , 2012, Clinical chemistry.

[18]  F. Staedtler,et al.  Perturbation of microRNAs in Rat Heart during Chronic Doxorubicin Treatment , 2012, PloS one.

[19]  F. Bertucci,et al.  Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis , 2012, Oncogene.

[20]  Offer Amir,et al.  Serum levels of microRNAs in patients with heart failure , 2012, European journal of heart failure.

[21]  H. Nonogi,et al.  Assessment of plasma miRNAs in congestive heart failure. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[22]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[23]  Qing Jing,et al.  MicroRNAs are dynamically regulated in hypertrophic hearts, and miR‐199a is essential for the maintenance of cell size in cardiomyocytes , 2010, Journal of cellular physiology.

[24]  Stefanie Dimmeler,et al.  Circulating MicroRNAs in Patients With Coronary Artery Disease , 2010, Circulation research.

[25]  Federica Limana,et al.  Circulating microRNAs are new and sensitive biomarkers of myocardial infarction , 2010, European heart journal.

[26]  Takeshi Kimura,et al.  Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway , 2010, Cardiovascular research.

[27]  Lakshmanane Boominathan.  The Tumor Suppressors p53, p63, and p73 Are Regulators of MicroRNA Processing Complex , 2010, PloS one.

[28]  Perry D Moerland,et al.  MiR423-5p As a Circulating Biomarker for Heart Failure , 2010, Circulation research.

[29]  Muneesh Tewari,et al.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). , 2010, Methods.

[30]  Juan Cinca,et al.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. , 2009, Journal of the American College of Cardiology.

[31]  Frank Speleman,et al.  A novel and universal method for microRNA RT-qPCR data normalization , 2009, Genome Biology.

[32]  D. Mulrooney,et al.  Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[34]  T. Çil,et al.  Use of N-Terminal Pro-Brain Natriuretic Peptide to Assess Left Ventricular Function after Adjuvant Doxorubicin Therapy in Early Breast Cancer Patients , 2009, Clinical drug investigation.

[35]  John McAnally,et al.  The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. , 2008, Developmental cell.

[36]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[37]  B. Hesse,et al.  BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity. , 2008, International journal of cardiology.

[38]  M. Somerfield,et al.  American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[40]  Kevin C Oeffinger,et al.  Chronic health conditions in adult survivors of childhood cancer. , 2006, The New England journal of medicine.

[41]  V. Valero,et al.  Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B. Hesse,et al.  Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction , 2004, European journal of heart failure.

[43]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[44]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[45]  J. Potter,et al.  Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[47]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[48]  K. Sridhar,et al.  Detection of Early Anthracycline Cardiotoxicity by Monitoring the Peak Filling Rate , 1993, American journal of clinical oncology.

[49]  H. Katus,et al.  S-troponin T in suspected ischemic myocardial injury compared with mass and catalytic concentrations of S-creatine kinase isoenzyme MB. , 1991, Clinical chemistry.